Lindahl was legal counsel to Senzime AB (publ) in connection with the company’s rights issue
Lindahl was legal counsel to Senzime AB (publ) in connection with the company’s rights issue which was resolved by the board of directors on 23 January 2023 and approved at an extraordinary general meeting on 16 February 2023.
The purpose of the rights issue is to enable the company’s continued growth journey. Through the rights issue, Senzime will receive proceeds of approximately SEK 91.9 million before deduction of transaction costs.
Senzime’s share is listed on Nasdaq Stockholm Main Market and the company develops, manufactures and markets CE- and FDA-cleared patient monitoring systems with the vision of a world without anesthesia- and respiratory-related complications.
Lindahl’s team consisted of Helena Lindbäck, Michaela Larsson, Erika Svensson and Mattias Prage.
Do you want to know more? Contact:
Helena Lindbäck
Counsel | AdvokatMichaela Larsson
Associate | AdvokatErika Svensson
Partner | AdvokatMattias Prage
Partner | AdvokatCarousel items
-
Cases and transactions
6/30/2026
Lindahl advises Disruptive Pharma in connection with reverse acquisition
Lindahl has acted as legal advisor to Disruptive Pharma Holding AB (publ) in connection with a reverse acquisition in which Guard Therapeutics International AB (publ) has entered into a conditional agreement to acquire all shares in Disruptive Pha...
-
Knowledge
6/29/2026
The scope of the Swedish FDI Act is expanded – is your business affected?
MCF's new regulation (MCFFS 2026:13) expands the scope of the Swedish FDI Act from 15 July 2026. Is your business affected? Read about the key changes.
-
News articles
6/25/2026
Lindahl recognised in IP Stars 2026
Lindahl advances to Tier 2 in Copyright & related rights in IP Stars 2026, retains strong rankings in trade mark law, and sees several lawyers recognised with individual awards.
-
Portraits
6/2/2026
Björn on M&A at Lindahl: "No two deals are alike"
Björn Andersson on M&A at Lindahl: how each transaction brings new challenges – and why no two deals are alike. Read about his experience and approach.
-
Read more news and insights?
